Watch Demo

Slovakia Antidiabetics Industry Outlook 2024 - 2028

See how Slovakia Antidiabetics performed compared to key markets such as Canada, Italy and Australia.

Key Market Indicators

Slovak Diabetes Medicine Sales are projected to climb to approximately $122 million by 2028, up from $106 million in 2023. This marks an average annual growth rate of 2.3%. Since 2001, the Slovak market has consistently expanded, posting an average yearly increase of 5.2%. In 2023, Slovakia held the seventh position globally, with Denmark leading the pack at $106 million. Italy, Australia, and Croatia secured the second, third, and fourth spots, respectively. Meanwhile, Slovak Insulin Exports are expected to reach about $6.1 million by 2028, rising from $5.1 million in 2023. This represents an average annual growth rate of 2.8%. Since 1999, Slovak insulin exports have surged by 9.8% year on year. In 2023, Slovakia ranked 20th, with Greece surpassing it at $5.1 million. France, Italy, and China occupied the second, third, and fourth positions in this category. On the import front, Slovak Insulin Imports are forecasted to hit nearly $40 million by 2028, increasing from $36.4 million in 2023. This reflects a compound annual growth rate (CAGR) of 1.2%. Since 1999, Slovak insulin imports have grown by 1.3% annually.

Marketing Banner

Slovakia Antidiabetics Market Data and Forecasts

How much will Slovakia Antidiabetics Market grow to 2028?

Forecast: Insulin in Dosage Market Size Value in Slovakia
Forecast: Import of Insulin in Dosage Forms to Slovakia
Forecast: Export of Insulin in Dosage Forms from Slovakia
Forecast: Import of Insulin in Dosage Forms to Slovakia
Forecast: Import of Insulin Not in Dosage Forms to Slovakia
More in Antidiabetics Industry for 2028